Inhibikase Therapeutics, Inc.

IKT

US45719W2052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
1.84 ^USD	+1.66%		+1.66%	+44.88%

05-21	HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating	MT
05-16	Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

August 24, 2023 at 08:30 am

Inhibikase Therapeutics, Inc. announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use.

Latest news about Inhibikase Therapeutics, Inc.

HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating	05-21	MT
Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024	05-16
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension	05-09	CI
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	04-03	CI
Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024	03-28
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501	03-27	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders	03-07	CI
Maxim Initiates Inhibikase Therapeutics With Buy Rating, Price Target is $8	02-20	MT
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers	02-07	CI
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	01-29	CI
Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024	01-16	CI
Inhibikase Therapeutics, Inc. Provides Update on Development Programs	12-19	CI
Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro	12-04	CI
Transcript : Inhibikase Therapeutics, Inc., Q3 2023 Earnings Call, Nov 15, 2023	11-15
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Reports Q3 Revenue $79.6M	11-14	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson?s Disease and Provides Update on Ongoing Enrollment	23-10-16	CI
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-04	MT
Sector Update: Health Care Stocks Lower Wednesday Afternoon	23-10-04	MT
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Potential Multiple System Atrophy Treatment	23-10-04	MT
Inhibikase Shares Rise Premarket on FDA Orphan Designation for Risvodetinib	23-10-04	DJ
Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib	23-08-24	CI
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro	23-08-17	CI

Chart Inhibikase Therapeutics, Inc.

Duration

Period

More charts

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinsonâs disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinsonâs disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinsonâs-related disorders of the brain and GI tract, orphan indications related to Parkinsonâs disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Companyâs RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Sector

Biotechnology & Medical Research

Calendar

2024-06-07 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.84 USD

Average target price

15.5 USD

Spread / Average Target

+742.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INHIBIKASE THERAPEUTICS, INC.	+44.88%	13.23M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research